secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001171843-23-003043
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose Q1 net loss widens to $13.7M; tuspetinib doublet dosing underway
-----------------------------------------------------------------------

- Net loss $13.7M ($0.15/sh) vs $11.5M ($0.12) YoY; R&D spend up to $8.8M.
- Cash and investments $35.7M; runway through March 2024.
- Tuspetinib APTIVATE trial: dose escalation/exploration complete; doublet with venetoclax dosing initiated with early blast reductions.
- Safety review: no drug-induced myelosuppression or DLTs up to 160mg/day in >70 patients.
- Anticipated FDA EOP1 meeting in Q2 2023 and clinical data presentation at EHA June 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184323003043/0001171843-23-003043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184323003043/f8k_050823.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-003043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer